SCHEMBL462437

SCHEMBL462437

Cc1nc2cc(-c3cccc(Cl)c3)nn2c(C(C)C)c1C(OC(C)(C)C)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.49
NPSR1 Q6W5P4 2/20 0.41
KMT2A Q03164 1/20 0.41
DPP4 P27487 1/20 0.41
DPP8 Q6V1X1 1/20 0.41
DPP9 Q86TI2 1/20 0.41
ABCB1 P08183 2/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP3A4 P08684 1/20 0.39
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL462780 1.00 NR1I2 (0.49) NR1I2NPSR1KMT2ADPP4DPP8
SCHEMBL457042 0.91 POLB (0.41) NR1I2NPSR1KMT2ADPP4DPP8
SCHEMBL457043 0.91 POLB (0.41) NR1I2NPSR1KMT2ADPP4DPP8
SCHEMBL462476 0.90 NR1I2 (0.51) NR1I2NPSR1KMT2ADPP4DPP8
SCHEMBL12079870 0.88 NR1I2 (0.59) NR1I2NPSR1KMT2ADPP4DPP8
SCHEMBL462612 0.88 NR1I2 (0.59) NR1I2NPSR1KMT2ADPP4DPP8
SCHEMBL10174791 0.87 NR1I2 (0.60) NR1I2NPSR1KMT2ADPP4DPP8
SCHEMBL462321 0.87 NR1I2 (0.49) NR1I2NPSR1KMT2ADPP4DPP8
SCHEMBL462975 0.87 NR1I2 (0.49) NR1I2NPSR1KMT2ADPP4DPP8
SCHEMBL462515 0.86 NR1I2 (0.55) NR1I2NPSR1KMT2ADPP4DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 US disclosed
EP-2614064-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION Bristol-Myers Squibb Company (US) 2013-07-17 EP disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 US disclosed
WO-2012033735-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication EIF2AK2, RTF2, MAVS NR1I2 3085/4885NPSR1 4620/4885KMT2A 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.